Aldose reductase is a tiny, cytosolic, monomeric enzyme that is a member of the aldo-keto reductase superfamily. Numerous aromatic and aliphatic carbonyl compounds are reduced by aldose reductase using the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH). It has been linked to the emergence of diabetic and galactosemic complications that affect the kidney, nerves, lens, and retina.
Aldose reductase is a crucial polyol pathway enzyme that, when activated under hyperglycemic conditions, causes the development of chronic diabetic complications. It is also a key factor in the promotion of inflammatory and cytotoxic conditions, even when blood sugar levels are normal. Aldose reductase is a fantastic drug target, and there is a lot of work being done to identify new substances that can inhibit it.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2361 | Epalrestat (ONO2235) | 82159-09-9 | Epalrestat (formerly also named ONO-2235) is a novel and potent aldose reductase inhibitor used for the treatment of diabetic neuropathy. |
|
V10871 | Alrestatin free acid | 51411-04-2 | Alrestatin is a specific inhibitor of the aldose reductase enzyme. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
